Warren Huff, President and CEO, Discusses Bardoxolone, Omaveloxolone, and a Possible Expansion of the CNS Pipeline with GEN Edge
In patients with chronic kidney disease caused by Alport syndrome (pictured), Reata Pharmaceuticals' met its primary and key secondary endpoints in the Phase III portion of the CARDINAL trial. Reata plans to use the positive results to support regulatory filings for marketing approval in the U.S. and internationally. [Arkana Laboratories]
Warren Huff, Reata’s president and CEO, discussed the clinical progress of omaveloxolone and bardoxolone, as well as the company’s approach to drug development, before the stock surge in an exclusive interview with GEN Edge during the recent J.P. Morgan conference in San Francisco . . .
